Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD
Status:
Terminated
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and effectiveness of bevasiranib given
either every 8 weeks or every 12 weeks after an initial pre-treatment with 3 injections of
Lucentis® (ranibizumab injection) compared to Lucentis® given every 4 weeks to people with
wet AMD. Patients will be assigned at random (like tossing a coin) to receive one of three
treatments options for 104 weeks.